Answers are grounded in this paper and cite their sources.
Protein replacement therapies for rare monogenic diseases have a higher probability of regulatory approval compared with biologics, small molecules, and grant-funded orphan drugs.
No takes yet. Share an insight, caveat, or question.
Gorzelany et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: